DELAWARE | 1-11083 | 04-2695240 |
(State or other | (Commission | (IRS employer |
jurisdiction of | file number) | identification no.) |
incorporation) |
One Boston Scientific Place, Natick, Massachusetts | 01760-1537 |
(Address of principal executive offices) | (Zip code) |
o | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Type of cost | Total estimated amount expected to be incurred |
Restructuring charges: | |
Termination benefits | $125 million to $150 million |
Other (1) | $20 million to $40 million |
Restructuring-related expenses: | |
Other (2) | $10 million to $20 million |
$155 million to $210 million |
Date: July 28, 2011 | BOSTON SCIENTIFIC CORPORATION | ||
By: | /s/ Timothy A. Pratt | ||
Timothy A. Pratt | |||
Executive Vice President, Chief Administrative | |||
Officer, General Counsel and Secretary | |||
Exhibit No. | Description |
99.1 | Press Release issued by Boston Scientific Corporation dated July 28, 2011. |
99.2 | Press Release issued by Boston Scientific Corporation dated July 28, 2011. |
• | Achieved second quarter sales of $1.975 billion, at the higher end of the Company's previous guidance range, and reported GAAP earnings of $0.10 per share, a 66 percent increase over the second quarter of 2010, and adjusted EPS of $0.17, a 42 percent increase over the second quarter of 2010, both exceeding previous guidance |
• | Received FDA approval and launched in the U.S. the IONTM Paclitaxel-Eluting Platinum Chromium Coronary Stent System, the Company's third-generation drug-eluting stent (DES) technology, driving its U.S. DES market share to 50 percent and maintaining its worldwide DES market leadership at 36 percent |
• | Launched the Company's next-generation ENERGENTM and PUNCTUATM cardiac resynchronization therapy defibrillator (CRT-D) systems and implantable cardioverter defibrillator (ICD) systems -- the world's smallest and thinnest high-energy devices to treat heart failure and sudden cardiac death -- in Europe and other international markets |
• | Increased Neuromodulation sales 16 percent, Peripheral Interventions sales 7 percent, Endoscopy sales 6 percent and Urology sales 6 percent, all on a worldwide constant currency basis, on the strength of new product introductions and continued adoption |
• | Reduced gross debt to $4.2 billion, consistent with the target capital structure, with the prepayment of the remaining $750 million of term loan borrowings during the quarter on the strength of $390 million of cash generated from operations ($468 million on an adjusted free cash flow basis), bringing total debt prepayment to over $1.8 billion during the past year |
• | Achieved investment grade status with Fitch Ratings and moved to positive outlook by Moody's Investor Services |
• | Announced a new program to repurchase up to $1.0 billion shares of common stock, which is in addition to the approximately 37 million shares remaining under a previous share repurchase program |
• | Announced a restructuring program aimed at increasing productivity, which is expected to generate gross annual savings of $225 million to $275 million exiting 2013, composed primarily of activities under the Company's corporate Zero-Based Budgeting Initiative and components of its Emerging Markets Initiative, and |
• | Announced an additional five-year, $150 million investment in China to leverage critical growth drivers, which include developing local manufacturing capabilities and building a Boston Scientific training center. In addition, the Company expects to increase its employee base in China from approximately 200 to more than 1,200 during the period. These initiatives are expected to drive an expansion of Boston Scientific's current sales force to approximately 700 employees and the creation of a fully staffed manufacturing infrastructure. During the second quarter, Boston Scientific received registration approval for the PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent from the State Food and Drug Administration of the People's Republic of China. The Company expects to launch the product in the fourth quarter of 2011. |
Change | ||||||||||||||
Three Months Ended | As Reported | Constant | ||||||||||||
June 30, | Currency | Currency | ||||||||||||
in millions | 2011 | 2010 | Basis | Basis | ||||||||||
Cardiac Rhythm Management | $ | 544 | $ | 527 | 3 | % | (2 | ) | % | |||||
Interventional Cardiology | 652 | 657 | (1 | ) | % | (6 | ) | % | ||||||
Peripheral Interventions | 189 | 166 | 14 | % | 7 | % | ||||||||
Cardiovascular Group | 841 | 823 | 2 | % | (3 | ) | % | |||||||
Electrophysiology | 38 | 37 | 2 | % | (1 | ) | % | |||||||
Endoscopy | 298 | 265 | 12 | % | 6 | % | ||||||||
Urology/Women's Health | 127 | 120 | 6 | % | 3 | % | ||||||||
Neuromodulation | 84 | 72 | 17 | % | 16 | % | ||||||||
Subtotal | 1,932 | 1,844 | 5 | % | 0 | % | ||||||||
Divested Businesses | 43 | 84 | N/A | N/A | ||||||||||
Worldwide | $ | 1,975 | $ | 1,928 | 2 | % | (2 | ) | % | |||||
• | $9 million ($12 million pre-tax) of intangible asset impairment charges associated with changes in the timing and amount of expected cash flows associated with certain acquired in-process research and development projects; |
• | $6 million ($7 million pre-tax) of contingent consideration expense; |
• | $21 million ($30 million pre-tax) of restructuring charges associated with the Company's 2010 Restructuring plan and Plant Network Optimization program, and |
• | $79 million ($96 million pre-tax) of amortization expense. |
Three Months Ended | Six Months Ended | |||||||||||||
June 30, | June 30, | |||||||||||||
in millions, except per share data | 2011 | 2010 | 2011 | 2010 | ||||||||||
Net sales | $ | 1,975 | $ | 1,928 | $ | 3,900 | $ | 3,888 | ||||||
Cost of products sold | 688 | 654 | 1,319 | 1,316 | ||||||||||
Gross profit | 1,287 | 1,274 | 2,581 | 2,572 | ||||||||||
Operating expenses: | ||||||||||||||
Selling, general and administrative expenses | 642 | 634 | 1,237 | 1,262 | ||||||||||
Research and development expenses | 223 | 232 | 435 | 485 | ||||||||||
Royalty expense | 52 | 57 | 103 | 108 | ||||||||||
Amortization expense | 96 | 124 | 228 | 252 | ||||||||||
Goodwill impairment (credits) charges | (31 | ) | 697 | 1,817 | ||||||||||
Intangible asset impairment charges | 12 | 12 | 60 | |||||||||||
Contingent consideration expense | 7 | 13 | ||||||||||||
Acquisition-related milestone | (250 | ) | ||||||||||||
Restructuring charges | 18 | 27 | 56 | 93 | ||||||||||
Gain on divestiture | (760 | ) | ||||||||||||
1,050 | 1,043 | 2,021 | 3,827 | |||||||||||
Operating income (loss) | 237 | 231 | 560 | (1,255 | ) | |||||||||
Other income (expense): | ||||||||||||||
Interest expense | (73 | ) | (103 | ) | (148 | ) | (195 | ) | ||||||
Other, net | (6 | ) | (9 | ) | 19 | (5 | ) | |||||||
Income (loss) before income taxes | 158 | 119 | 431 | (1,455 | ) | |||||||||
Income tax expense | 12 | 21 | 239 | 36 | ||||||||||
Net income (loss) | $ | 146 | $ | 98 | $ | 192 | $ | (1,491 | ) | |||||
Net income (loss) per common share - basic | $ | 0.10 | $ | 0.06 | $ | 0.12 | $ | (0.98 | ) | |||||
Net income (loss) per common share - assuming dilution | $ | 0.10 | $ | 0.06 | $ | 0.12 | $ | (0.98 | ) | |||||
Weighted-average shares outstanding | ||||||||||||||
Basic | 1,528.6 | 1,516.6 | 1,527.5 | 1,515.6 | ||||||||||
Assuming dilution | 1,535.8 | 1,525.3 | 1,536.0 | 1,515.6 | ||||||||||
As of | |||||||||
June 30, | December 31, | ||||||||
in millions, except share data | 2011 | 2010 | |||||||
(Unaudited) | |||||||||
ASSETS | |||||||||
Current assets: | |||||||||
Cash and cash equivalents | $ | 154 | $ | 213 | |||||
Trade accounts receivable, net | 1,334 | 1,320 | |||||||
Inventories | 927 | 894 | |||||||
Deferred income taxes | 417 | 429 | |||||||
Assets held for sale | 7 | 576 | |||||||
Prepaid expenses and other current assets | 310 | 183 | |||||||
Total current assets | 3,149 | 3,615 | |||||||
Property, plant and equipment, net | 1,702 | 1,697 | |||||||
Goodwill | 9,758 | 10,186 | |||||||
Other intangible assets, net | 6,684 | 6,343 | |||||||
Other long-term assets | 266 | 287 | |||||||
$ | 21,559 | $ | 22,128 | ||||||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||
Current liabilities: | |||||||||
Current debt obligations | $ | 4 | $ | 504 | |||||
Accounts payable | 223 | 184 | |||||||
Accrued expenses | 1,329 | 1,626 | |||||||
Other current liabilities | 336 | 295 | |||||||
Total current liabilities | 1,892 | 2,609 | |||||||
Long-term debt | 4,197 | 4,934 | |||||||
Deferred income taxes | 1,916 | 1,644 | |||||||
Other long-term liabilities | 2,014 | 1,645 | |||||||
Commitments and contingencies | |||||||||
Stockholders' equity | |||||||||
Preferred stock, $.01 par value - authorized 50,000,000 | |||||||||
shares, none issued and outstanding | |||||||||
Common stock, $.01 par value - authorized 2,000,000,000 | |||||||||
shares, issued 1,528,799,782 shares as of June 30, 2011 and | 15 | 15 | |||||||
1,520,780,112 shares as of December 31, 2010 | |||||||||
Additional paid-in capital | 16,278 | 16,232 | |||||||
Accumulated deficit | (4,630 | ) | (4,822 | ) | |||||
Other stockholders' deficit | (123 | ) | (129 | ) | |||||
Total stockholders' equity | 11,540 | 11,296 | |||||||
$ | 21,559 | $ | 22,128 | ||||||
Three Months Ended June 30, | |||||||||||||||
2011 | 2010 | ||||||||||||||
Impact | Impact | ||||||||||||||
Net | per diluted | Net | per diluted | ||||||||||||
in millions, except per share data | income | share | income | share | |||||||||||
GAAP net income | $ | 146 | $ | 0.10 | $ | 98 | $ | 0.06 | |||||||
Non-GAAP adjustments: | |||||||||||||||
Goodwill impairment credit | (31 | ) | (0.02 | ) | |||||||||||
Intangible asset impairment charges | 9 | 0.01 | |||||||||||||
Acquisition-related charges | 6 | 0.00 | |||||||||||||
Divestiture-related charges | 1 | 0.00 | |||||||||||||
Restructuring-related charges | 21 | 0.01 | 29 | 0.02 | |||||||||||
Amortization expense | 79 | 0.05 | 94 | 0.06 | |||||||||||
Adjusted net income | $ | 262 | $ | 0.17 | $ | 190 | $ | 0.12 | |||||||
Six Months Ended June 30, | |||||||||||||||
2011 | 2010 | ||||||||||||||
Impact | Net | Impact | |||||||||||||
Net | per diluted | (loss) | per diluted | ||||||||||||
in millions, except per share data | income | share | income | share | |||||||||||
GAAP net income (loss) | $ | 192 | $ | 0.12 | $ | (1,491 | ) | $ | (0.98 | ) | |||||
Non-GAAP adjustments: | |||||||||||||||
Goodwill impairment charges | 697 | 0.45 | 1,817 | 1.20 | * | ||||||||||
Intangible asset impairment charges | 9 | 0.00 | 51 | 0.03 | * | ||||||||||
Acquisition-related net credits | (23 | ) | (0.01 | ) | (216 | ) | (0.14 | ) | * | ||||||
Divestiture-related net credits | (530 | ) | (0.34 | ) | |||||||||||
Restructuring-related charges | 56 | 0.04 | 85 | 0.05 | * | ||||||||||
Discrete tax items | 4 | 0.00 | |||||||||||||
Amortization expense | 193 | 0.13 | 195 | 0.13 | * | ||||||||||
Adjusted net income | $ | 598 | $ | 0.39 | $ | 441 | $ | 0.29 | |||||||
Three Months Ended | Six Months Ended | |||||||||||||
in millions | June 30, | June 30, | ||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||
Goodwill impairment net (credits) charges: | ||||||||||||||
Goodwill impairment credits | $ | (31 | ) | $ | (31 | ) | ||||||||
Goodwill impairment charge | $ | 697 | 1,848 | |||||||||||
(31 | ) | 697 | 1,817 | |||||||||||
Income tax benefit (a) | ||||||||||||||
Goodwill impairment net (credits) charges, net of tax | $ | (31 | ) | $ | 697 | $ | 1,817 | |||||||
Intangible asset impairment charges: | ||||||||||||||
Intangible asset impairment charges | $ | 12 | $ | 12 | $ | 60 | ||||||||
Income tax benefit (a) | (3 | ) | (3 | ) | (9 | ) | ||||||||
Intangible asset impairment charges, net of tax | $ | 9 | $ | 9 | $ | 51 | ||||||||
Acquisition-related net charges (credits): | ||||||||||||||
Contingent consideration expense | $ | 7 | $ | 13 | ||||||||||
Acquisition-related milestone | $ | (250 | ) | |||||||||||
Acquisition-related costs (b) | 2 | |||||||||||||
Inventory step-up adjustment (c) | 1 | |||||||||||||
Gain on previously held equity interests (d) | (38 | ) | ||||||||||||
7 | (22 | ) | (250 | ) | ||||||||||
Income tax expense (a) | (1 | ) | (1 | ) | 34 | |||||||||
Acquisition-related net charges (credits), net of tax | $ | 6 | $ | (23 | ) | $ | (216 | ) | ||||||
Divestiture-related net charges (credits): | ||||||||||||||
Gain on divestiture | $ | (760 | ) | |||||||||||
Divestiture-related costs (c) | $ | 1 | 2 | |||||||||||
1 | (758 | ) | ||||||||||||
Income tax expense (a) | 228 | |||||||||||||
Divestiture-related net charges (credits), net of tax | $ | 1 | $ | (530 | ) | |||||||||
Restructuring-related charges: | ||||||||||||||
Restructuring charges | $ | 18 | $ | 27 | $ | 56 | $ | 93 | ||||||
Restructuring-related charges (e) | 12 | 14 | 24 | 28 | ||||||||||
30 | 41 | 80 | 121 | |||||||||||
Income tax benefit (a) | (9 | ) | (12 | ) | (24 | ) | (36 | ) | ||||||
Restructuring-related charges, net of tax | $ | 21 | $ | 29 | $ | 56 | $ | 85 | ||||||
Discrete tax items: | ||||||||||||||
Income tax benefit (a) | $ | 4 | ||||||||||||
Amortization expense: | ||||||||||||||
Amortization expense | $ | 96 | $ | 124 | $ | 228 | $ | 252 | ||||||
Income tax benefit (a) | (17 | ) | (30 | ) | (35 | ) | (57 | ) | ||||||
Amortization expense, net of tax | $ | 79 | $ | 94 | $ | 193 | $ | 195 |
Change | ||||||||||||||
Three Months Ended | As Reported | Constant | ||||||||||||
June 30, | Currency | Currency | ||||||||||||
in millions | 2011 | 2010 | Basis | Basis | ||||||||||
United States | $ | 1,040 | $ | 1,046 | (1 | ) | % | (1 | ) | % | ||||
EMEA | 459 | 421 | 9 | % | (3 | ) | % | |||||||
Japan | 235 | 209 | 12 | % | 0 | % | ||||||||
Inter-Continental | 198 | 168 | 18 | % | 8 | % | ||||||||
International | 892 | 798 | 12 | % | 0 | % | ||||||||
Subtotal | 1,932 | 1,844 | 5 | % | 0 | % | ||||||||
Divested Businesses | 43 | 84 | N/A | N/A | ||||||||||
Worldwide | $ | 1,975 | $ | 1,928 | 2 | % | (2 | ) | % | |||||
Change | ||||||||||||||
Three Months Ended | As Reported | Constant | ||||||||||||
June 30, | Currency | Currency | ||||||||||||
in millions | 2011 | 2010 | Basis | Basis | ||||||||||
Cardiac Rhythm Management | $ | 544 | $ | 527 | 3 | % | (2 | ) | % | |||||
Interventional Cardiology | 652 | 657 | (1 | ) | % | (6 | ) | % | ||||||
Peripheral Interventions | 189 | 166 | 14 | % | 7 | % | ||||||||
Cardiovascular Group | 841 | 823 | 2 | % | (3 | ) | % | |||||||
Electrophysiology | 38 | 37 | 2 | % | (1 | ) | % | |||||||
Endoscopy | 298 | 265 | 12 | % | 6 | % | ||||||||
Urology/Women's Health | 127 | 120 | 6 | % | 3 | % | ||||||||
Neuromodulation | 84 | 72 | 17 | % | 16 | % | ||||||||
Subtotal | 1,932 | 1,844 | 5 | % | 0 | % | ||||||||
Divested Businesses | 43 | 84 | N/A | N/A | ||||||||||
Worldwide | $ | 1,975 | $ | 1,928 | 2 | % | (2 | ) | % | |||||
Change | ||||||||||||||
Six Months Ended | As Reported | Constant | ||||||||||||
June 30, | Currency | Currency | ||||||||||||
in millions | 2011 | 2010 | Basis | Basis | ||||||||||
United States | $ | 2,063 | $ | 2,082 | (1 | ) | % | (1 | ) | % | ||||
EMEA | 912 | 870 | 5 | % | (1 | ) | % | |||||||
Japan | 470 | 435 | 8 | % | (3 | ) | % | |||||||
Inter-Continental | 378 | 328 | 15 | % | 8 | % | ||||||||
International | 1,760 | 1,633 | 8 | % | 0 | % | ||||||||
Subtotal | 3,823 | 3,715 | 3 | % | 0 | % | ||||||||
Divested Businesses | 77 | 173 | N/A | N/A | ||||||||||
Worldwide | $ | 3,900 | $ | 3,888 | 0 | % | (3 | ) | % | |||||
Change | ||||||||||||||
Six Months Ended | As Reported | Constant | ||||||||||||
June 30, | Currency | Currency | ||||||||||||
in millions | 2011 | 2010 | Basis | Basis | ||||||||||
Cardiac Rhythm Management | $ | 1,103 | $ | 1,065 | 4 | % | 1 | % | ||||||
Interventional Cardiology | 1,288 | 1,347 | (4 | ) | % | (8 | ) | % | ||||||
Peripheral Interventions | 365 | 331 | 10 | % | 6 | % | ||||||||
Cardiovascular Group | 1,653 | 1,678 | (1 | ) | % | (5 | ) | % | ||||||
Electrophysiology | 74 | 75 | (1 | ) | % | (3 | ) | % | ||||||
Endoscopy | 585 | 525 | 11 | % | 7 | % | ||||||||
Urology/Women's Health | 247 | 232 | 6 | % | 4 | % | ||||||||
Neuromodulation | 161 | 140 | 16 | % | 15 | % | ||||||||
Subtotal | 3,823 | 3,715 | 3 | % | 0 | % | ||||||||
Divested Businesses | 77 | 173 | N/A | N/A | ||||||||||
Worldwide | $ | 3,900 | $ | 3,888 | 0 | % | (3 | ) | % | |||||
Q2 2011 Net Sales as compared to Q2 2010 | ||||||||||
Change | Estimated | |||||||||
As Reported | Constant | Impact of | ||||||||
Currency | Currency | Foreign | ||||||||
in millions | Basis | Basis | Currency | |||||||
United States | $ | (6 | ) | $ | (6 | ) | ||||
EMEA | 38 | (12 | ) | $ | 50 | |||||
Japan | 26 | (1 | ) | 26 | ||||||
Inter-Continental | 30 | 14 | 17 | |||||||
International | 94 | 1 | 93 | |||||||
Subtotal | 88 | (5 | ) | 93 | ||||||
Divested Businesses | (41 | ) | (44 | ) | 3 | |||||
Worldwide | $ | 47 | $ | (49 | ) | $ | 96 | |||
Q2 2011 Net Sales as compared to Q2 2010 | ||||||||||
Change | Estimated | |||||||||
As Reported | Constant | Impact of | ||||||||
Currency | Currency | Foreign | ||||||||
in millions | Basis | Basis | Currency | |||||||
Cardiac Rhythm Management | $ | 17 | $ | (10 | ) | $ | 27 | |||
Interventional Cardiology | (5 | ) | (39 | ) | 34 | |||||
Peripheral Interventions | 23 | 12 | 11 | |||||||
Cardiovascular Group | 18 | (27 | ) | 45 | ||||||
Electrophysiology | 1 | 0 | 1 | |||||||
Endoscopy | 33 | 16 | 17 | |||||||
Urology/Women's Health | 7 | 4 | 3 | |||||||
Neuromodulation | 12 | 12 | 0 | |||||||
Subtotal | 88 | (5 | ) | 93 | ||||||
Divested Businesses | (41 | ) | (44 | ) | 3 | |||||
Worldwide | $ | 47 | $ | (49 | ) | $ | 96 | |||
Q2 2011 YTD Net Sales as compared to Q2 2010 YTD | ||||||||||
Change | Estimated | |||||||||
As Reported | Constant | Impact of | ||||||||
Currency | Currency | Foreign | ||||||||
in millions | Basis | Basis | Currency | |||||||
United States | $ | (19 | ) | $ | (19 | ) | ||||
EMEA | 42 | (9 | ) | $ | 51 | |||||
Japan | 35 | (14 | ) | 49 | ||||||
Inter-Continental | 50 | 25 | 25 | |||||||
International | 127 | 2 | 125 | |||||||
Subtotal | 108 | (17 | ) | 125 | ||||||
Divested Businesses | (96 | ) | (100 | ) | 4 | |||||
Worldwide | $ | 12 | $ | (117 | ) | $ | 129 | |||
Q2 2011 YTD Net Sales as compared to Q2 2010 YTD | ||||||||||
Change | Estimated | |||||||||
As Reported | Constant | Impact of | ||||||||
Currency | Currency | Foreign | ||||||||
in millions | Basis | Basis | Currency | |||||||
Cardiac Rhythm Management | $ | 38 | $ | 6 | $ | 32 | ||||
Interventional Cardiology | (59 | ) | (107 | ) | 48 | |||||
Peripheral Interventions | 34 | 19 | 15 | |||||||
Cardiovascular Group | (25 | ) | (88 | ) | 63 | |||||
Electrophysiology | (1 | ) | (2 | ) | 1 | |||||
Endoscopy | 60 | 36 | 24 | |||||||
Urology/Women's Health | 15 | 10 | 5 | |||||||
Neuromodulation | 21 | 21 | 0 | |||||||
Subtotal | 108 | (17 | ) | 125 | ||||||
Divested Businesses | (96 | ) | (100 | ) | 4 | |||||
Worldwide | $ | 12 | $ | (117 | ) | $ | 129 | |||
in millions | U.S. | International | Worldwide | ||||||||||||||||||
Q2 2011 | Q2 2010 | Q2 2011 | Q2 2010 | Q2 2011 | Q2 2010 | ||||||||||||||||
Defibrillator systems | $ | 243 | $ | 238 | * | $ | 150 | $ | 141 | $ | 393 | $ | 379 | ||||||||
Pacemaker systems | 72 | 84 | 79 | 64 | 151 | 148 | |||||||||||||||
Total CRM products | $ | 315 | $ | 322 | $ | 229 | $ | 205 | $ | 544 | $ | 527 |
in millions | U.S. | International | Worldwide | ||||||||||||||||||
Q2 2011 | Q2 2010 | Q2 2011 | Q2 2010 | Q2 2011 | Q2 2010 | ||||||||||||||||
Drug-eluting stent systems | $ | 208 | $ | 209 | $ | 192 | $ | 180 | $ | 400 | $ | 389 | |||||||||
Bare-metal stent systems | 8 | 12 | 20 | 21 | 28 | 33 | |||||||||||||||
Total coronary stent systems | $ | 216 | $ | 221 | $ | 212 | $ | 201 | $ | 428 | $ | 422 |
in millions | U.S. | International | Worldwide | ||||||||||||||||||
YTD 2011 | YTD 2010 | YTD 2011 | YTD 2010 | YTD 2011 | YTD 2010 | ||||||||||||||||
Defibrillator systems | $ | 509 | $ | 484 | * | $ | 301 | $ | 285 | $ | 810 | $ | 769 | ||||||||
Pacemaker systems | 145 | 164 | 148 | 132 | 293 | 296 | |||||||||||||||
Total CRM products | $ | 654 | $ | 648 | $ | 449 | $ | 417 | $ | 1,103 | $ | 1,065 |
in millions | U.S. | International | Worldwide | ||||||||||||||||||
YTD 2011 | YTD 2010 | YTD 2011 | YTD 2010 | YTD 2011 | YTD 2010 | ||||||||||||||||
Drug-eluting stent systems | $ | 392 | $ | 419 | $ | 387 | $ | 377 | $ | 779 | $ | 796 | |||||||||
Bare-metal stent systems | 17 | 24 | 41 | 46 | 58 | 70 | |||||||||||||||
Total coronary stent systems | $ | 409 | $ | 443 | $ | 428 | $ | 423 | $ | 837 | $ | 866 |
Three Months Ended June 30, 2011 | |||
in millions | |||
Cash generated from operations | $ | 390 | |
Less: Capital expenditures | 82 | ||
Free cash flow | 308 | ||
Plus: Restructuring payments | 38 | ||
Plus: Special tax items | 122 | ||
Adjusted free cash flow | $ | 468 | |
Change | ||||||||||||||
Three Months Ended | As Reported | Constant | ||||||||||||
June 30, | Currency | Currency | ||||||||||||
in millions | 2011 | 2010 | Basis | Basis | ||||||||||
Urology | $ | 87 | $ | 80 | 9 | % | 6 | % | ||||||
Women's Health | 40 | 40 | 0 | % | (3 | ) | % | |||||||
Urology/Women's Health | $ | 127 | $ | 120 | 6 | % | 3 | % |
Q2 2011 Net Sales as compared to Q2 2010 | ||||||||||
Change | Estimated | |||||||||
As Reported | Constant | Impact of | ||||||||
Currency | Currency | Foreign | ||||||||
in millions | Basis | Basis | Currency | |||||||
Urology | $ | 7 | $ | 5 | $ | 2 | ||||
Women's Health | 0 | (1 | ) | 1 | ||||||
Urology/Women's Health | $ | 7 | 4 | $ | 3 |
Q3 2011 Estimate | Full Year 2011 Estimate | ||||||||||||
(Low) | (High) | (Low) | (High) | ||||||||||
GAAP results | $ | 0.03 | $ | 0.08 | $ | 0.22 | $ | 0.30 | |||||
Goodwill impairment charge | 0.45 | 0.45 | |||||||||||
Other intangible asset impairment charges | 0.01 | 0.01 | |||||||||||
Estimated acquisition-related net charges | 0.01 | 0.00 | 0.00 | 0.00 | |||||||||
Estimated divestiture-related net charges (credits) | 0.00 | 0.00 | (0.34 | ) | (0.35 | ) | |||||||
Estimated restructuring-related charges | 0.02 | 0.01 | 0.07 | 0.06 | |||||||||
Discrete tax items | 0.00 | 0.00 | |||||||||||
Estimated amortization expense | 0.05 | 0.05 | 0.23 | 0.23 | |||||||||
Adjusted results | $ | 0.11 | $ | 0.14 | $ | 0.64 | $ | 0.70 | |||||
Goodwill and other intangible asset impairment charges (credits) - These amounts represent non-cash write-downs and related true-ups of the Company's goodwill balance attributable to its U.S. Cardiac Rhythm Management business, as well as certain intangible asset balances. Management removes the impact of these charges (credits) from the Company's operating performance to assist in assessing the Company's cash generated from operations. Management believes this is a critical metric for the Company in measuring the Company's ability to generate cash and pay down debt. Therefore, these charges (credits) are excluded from management's assessment of operating performance and are also excluded from the measures management uses to set employee compensation. Accordingly, management has excluded these charges (credits) for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of the Company's current operating performance and a comparison to the Company's past operating performance, particularly in terms of liquidity. |
Acquisition-related (credits) charges - These adjustments consist of (a) acquisition-related gains on previously held equity interests, (b) contingent consideration expense, (c) a gain on an acquisition-related milestone receipt, (d) due diligence, other fees and exit costs, and (e) an inventory step-up adjustment. The acquisition-related gains on previously held equity interests is a non-recurring benefit associated with acquisitions completed in the first quarter of 2011. Contingent consideration expense is a non-cash charge representing accounting adjustments to state contingent consideration liabilities at their estimated fair value. These adjustments can be highly variable depending on the assessed likelihood and amount of future contingent consideration payments. The gain on an acquisition-related milestone receipt resulted from a 2010 receipt related to Guidant Corporation's sale of its vascular intervention and endovascular solutions businesses to Abbott Laboratories, and is not indicative of future operating results. Due diligence, other fees and exit costs include legal, tax and other one time expenses associated with prior acquisitions that are not representative of on-going operations. The inventory step-up adjustment is a non-cash charge related to acquired inventory directly attributable to prior acquisitions and is not indicative of the Company's on-going operations, or on-going cost of products sold. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of the Company's current operating performance and a comparison to the Company's past operating performance. |
Divestiture-related (credits) charges - These amounts represent (a) gains resulting from business divestitures and (b) fees and separation costs associated with business divestitures. The Company completed the sale of its Neurovascular business in January 2011 and the resulting gain is not indicative of future operating performance and is not used by management to assess operating performance. Fees and separation costs represent those associated with the Company's divestiture of its Neurovascular business and are not representative of on-going operations. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of the Company's current operating performance and a comparison to the Company's past operating performance. |
Restructuring and restructuring-related costs - These adjustments represent primarily severance, fixed asset write-offs, costs to transfer production lines from one facility to another, and other costs associated with the Company's 2010 Restructuring plan, Plant Network Optimization program and 2007 Restructuring plan. These expenses are excluded by management in assessing the Company's operating performance, as well as from the Company's operating segments' measures of profit and loss used for making operating decisions and assessing performance. Accordingly, management excluded these charges for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of the Company's current operating performance and a comparison to the Company's past operating performance. |
Discrete tax items - These items represent adjustments of certain tax positions, which were initially established in prior periods as a result of intangible asset impairment charges; acquisition-, divestiture-, restructuring- or litigation-related charges (credits). These adjustments do not reflect expected on-going operating results. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of the Company's current operating performance and for comparison to the Company's past operating performance. |
Amortization expense - Amortization expense is a non-cash charge and does not impact the Company's liquidity or compliance with the covenants included in its debt agreements. Management removes the impact of amortization from the Company's operating performance to assist in assessing the Company's cash generated from operations. Management believes this is a critical metric for the Company in measuring the Company's ability to generate cash and pay down debt. Therefore, amortization expense is excluded from management's assessment of operating performance and is also excluded from the measures management uses to set employee compensation. Accordingly, management has excluded amortization expense for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of the Company's current operating performance, particularly in terms of liquidity. |
Changes in foreign currency exchange rates - The impact of changes in foreign currency exchange rates is highly variable and difficult to predict. Accordingly, management excludes the impact of changes in foreign currency exchange rates for purposes of reviewing regional and divisional revenue growth rates to facilitate an evaluation of the Company's current operating performance and comparison to the Company's past operating performance. |
Capital expenditures - This adjustment represents additions to property, plant and equipment necessary to fund the Company's future growth. The Company adjusts its cash generated from operations by these recurring expenditures, as management believes this measurement to be useful as an indicator of the Company's ability to service its debt, meet other payment obligations and make strategic acquisitions and fund other corporate initiatives. Accordingly, management included these payments to facilitate an evaluation of the Company's current operating performance and comparison to the Company's past operating performance. |
Restructuring payments - This adjustment represents cash payments associated primarily with severance, costs to transfer production lines from one facility to another and other costs associated with the Company's 2010 Restructuring plan, Plant Network Optimization program and 2007 Restructuring plan. These represent non-operational uses of cash and are excluded from the calculation of the covenants included in the Company's revolving credit facility agreement. Accordingly, management adds back these payments to cash generated from operations for purposes of calculating this non-GAAP financial measure in order to facilitate an evaluation of the Company's current operating cash flow and a comparison to the Company's past operating cash flow. |
Special tax items - This adjustment represents net tax amounts associated with the Company's sale of its Neurovascular business, and are not indicative of future periods or comparable to prior periods. Accordingly, management adds back these items to cash generated from operations for purposes of calculating this non-GAAP financial measure in order to facilitate an evaluation of the Company's current operating cash flow and a comparison to the Company's past operating cash flow. |
&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2?ON[\G
M(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX*/'@Z>&UP;65T82!X
M;6QN K*+FK84,(I=J-2<*@^:U^=/]CHMOK(
M;C;E*D8J#\QP_P!GH\WR`Q0PV^4[-QRK@-K;JIDRF!F;PRT]7]Y$A5(H45?,
M\R2\Z1S;@6)]A39)3-:';Y.^>,T;U%/\'7MO8&V6V9PTT>#T8'XZ[_K-RL,3
MDJ2F7#Y3!3[9RLF0$T=-782:3Q"1Z4(YAEPDTQ>-V(M&Q`M>ZDF^V2V_ZB.?
M%5]:@<0PS^>KS^?1=NEN(U\5:^*&U"GKZ?F.FRJVMN+I+MM\MBZ(IMRFJ(L+
MN7.5L93!U.'R*1-CJ@4K.KY&+0X\@6\:H&1F`8^[BX@WC;/!D>LY&I5'Q!AQ
M%?+Y?D:=/1S17]H$<][+4`'((X_9\O/SZJI_F!?'3%=9;JGWGAZ6IDI:A!N+
M;GFJ%G\^WJV5H/X>DK!;2[5JXWHI`H4^***3G66]R+R1OS[C:K;3D>*G:U,=
MP''['%&^VH\NC2QF^K@5BWZJG2WVCS_VPH?S^75(/9&X H,F]NI;7F.QV[F/E
MUOK)V,46X6J!J`C/B_T*#.HX\O3I(9[='7/1FT\'B:JCR,6W\AD,KC:'%4-%
M_%ZZO?(&KRFX*RKI83`9*>=JR0R)"+MK*QJ2I]E*0WF[W5Q/&%$I-?05]!U)
MFY[GRI[3\NV7*US;SWMO=>)X@0`N0]3(Y6N`?(#.*])7K$X/8%'13=4YZ/-]
M-;IKPZX=,A)#D]DY.L<(7I8:G[>J^U)`1X)0"RJ+:9!ZS23;Y+]%26$Q;@BX
MK\+J/0^O47\K0M9WE-!Q7T/D?S_P`/0?YQY:W#VQYIM=PV^5DV
M:>;5:S>4,A-3`YX:6K1:X\O/HSS;7V;OK(8?.[PV7B:K>&Q,G%"D&2,]35[4
MSM(GFA6*6GJHJ7+XN6*05.-J)DFBFIG5EY!`+;D7VWE[-IF\#B/0@^8ZGGES
M:N2/<<6?,M_LT9Y@MG4RK4BDJ\&*@T<'B"1T#7S-W+O?$[4ZREVYN;.XG`YO
M?[[8FLW)EC_`*7A>*OV#HG6XMF?)?XI=Y9S
M=6YNBL[UYB=_Q-D
SC=[B4B:.SW>W=9T5J3.-,=15?#CD6I%1B20Z?X4(&KH17-S%8U7;]
MWCDNYE#'QV<11*PX1QNM'!XAW[?1//HHV[-Z87I>EWOOZ27I'O'-;^R,0S>V
M*O%=1=I]A[CAFDCFDEVFC8REWG@\;BZ>G)6!)J*C@5?$L\-[>[;)#O=Z+?;M
MT6!MA%5:=)77PG85#,T